Compare Chipotle Mexican Grill, Inc. (CMG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Novo Nordisk A/S — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.73 (market cap $40.49B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.1× Chipotle Mexican Grill, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| CMG | NVO | |
|---|---|---|
Market Cap | $40.49B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $63.98 |
52-Week Low | $28.17 | $35.29 |
Enterprise Value | $45.24B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMG trades at $32.71, up 1.76% on the day, with a bearish technical signal driven by moving averages. The company reported strong revenue growth to $11.93B in 2025 and has consistently beaten EPS estimates in recent quarters. However, net cash flow turned negative at -$392M due to aggressive financing activities. Recent news highlights a salmonella outbreak linked to jalapeños, creating near-term headwinds.
Wall Street maintains a bullish stance with a $42.17 consensus price target, representing 29% upside, and no sell ratings. Key risks include food safety issues, margin compression, and negative cash flow. The stock's high P/E of 29.63 requires sustained earnings growth to justify valuation.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
